Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach

Journal of Medicinal Chemistry

Volumn 47, Issue 17, 2004, Pages 4258-4267

  Parenti, Marco Daniele ^a   Pacchioni, Sara ^a   Ferrari, Anna Maria ^a   Rastelli, Giulio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ALDOSE REDUCTASE INHIBITOR; ANTIMALARIAL AGENT; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR;

ARTICLE; CRYSTALLOGRAPHY; DRUG BINDING; DRUG BINDING SITE; DRUG COST; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; PLASMODIUM FALCIPARUM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ALDEHYDE REDUCTASE; ANIMALS; ANTIMALARIALS; BINDING SITES; FOLIC ACID ANTAGONISTS; MODELS, MOLECULAR; PLASMODIUM FALCIPARUM; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 3843137418     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040769c     Document Type: Article

References (35)

1. Warhurst, D. C. Antimalarial drug discovery development of inhibitors of dihydrofolate reductase active in drug desistance. Drug Discovery Today 1998, 3, 538-546.
2. Warhurst, D. C. Resistance to antifolates in Plasmodium falciparum, the causative agent of tropical malaria. Sci. Prog. 2002, 85, 89-111.
3. Sirawaraporn, W. Dihydrofolate reductase and antifolate resistance in malaria. Drug Resist. Updates 1998, 1, 397-406.
4. Yuthavong, Y. Basis for antifolates action and resistance in malaria. Microbes Infect. 2002, 4, 175-182.
5. Wirth, D. Malaria: a 21st century solution for an ancient disease. Nat. Med. 1998, 4, 1360-1362.
6. Lemcke, T.; Christensen, I. T.; Jorgensen, F. S. Towards an understanding of drug resistance in malaria: three-dimensional structure of Plasmodium falciparum dihydrofolate reductase by homology building. Bioorg. Med. Chem. 1999, 7, 1003-1011.
7. Rastelli, G.; Sirawaraporn, W.; Sompornpisut, P.; Vilaivan, T.; Kamchonwongpaisan, S.; Quarrell, R.; Lowe, G.; Thebtaranonth, Y.; Yuthavong, Y. Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with Plasmodium falciparum dihydrofolate reductase: structural basis of antifolate resistance. Bioorg. Med. Chem. 2000, 8, 1117-1128.
8. Delfino, R. T.; Santos-Filho, O. A.; Figueroa-Villar, J. D. Molecular modeling of wild-type and antifolate resistant mutant Plasmodium falciparum DHFR. Biophys. Chem. 2002, 98, 287-300.
9. Yuthavong, Y.; Vilaivan, T.; Chareonsethakul, N.; Kamchonwongpaisan, S.; Sirawaraporn, W.; Quarrell, R.; Lowe, G. Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum. J. Med. Chem. 2000, 43, 2738-2744.
10. Yuvaniyama, J.; Chitnumsub, P.; Kamchonwongpaisan, S.; Vanichtanankul, J.; Sirawaraporn, W.; Taylor, P.; Walkinshaw, M. D.; Yuthavong, Y. Insight into antifolate resistance from malarial DHFR-TS structures. Nat. Sruct. Biol. 2003, 10, 357-365.
11. Rastelli, G.; Pacchioni, S.; Sirawaraporn, W.; Sirawaraporn, R.; Parenti, M. D.; Ferrari, A. M. Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors. J. Med. Chem. 2003, 46, 2834-2845.
12. Palomer, A.; Cabre, F.; Pascual, J.; Campos, J.; Trujillo, M. A.; Entrena, A.; Gallo, M. A.; Garcia, L.; Mauleon, D.; Espinosa, A. Identification of Novel Cyclooxygenase-2 Selective Inhibitors Using Pharmacophore Models. J. Med. Chem. 2002, 45, 1402-1411.
13. Ekins, S.; Kim, R. B.; Leake, B. F.; Dantzig, A. H.; Schuetz, E. G.; Lan, L.; Yasuda, K.; Shepard, R. L.; Winter, M. A.; Schuetz, J. D.; Wikel, J. H.; Wrighton, S. A. Application of Three-Dimensional Quantitative Structure-Activity Relationships of P-Glycoprotein Inhibitors and Substrates. Mol. Pharmacol. 2002, 61, 974-981.
14. 2- Adrenoceptores. J. Med. Chem. 2001, 44, 2118-2132.
15. Bureau, R.; Daveu, C.; Lancelot, J.; Rault, S. Molecular Design Based on 3D-Pharmacophore. Application to 5-HT Subtypes Receptors. J. Chem. Inf. Comput. Sci. 2002, 42, 429-436.
16. Debnath, A. K. Pharmacophore mapping of a series of 2,2-diamino-5- deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase. J. Med. Chem. 2002, 45, 41-53.
17. Debnath, A. K. Generation of predictive pharmacophore models for CCR5 antagonists: study with pteridine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors. J. Med. Chem. 2003, 46, 4501-4515.
18. Krovat, E. M.; Langer, T. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J. Med. Chem. 2003, 46, 716-726.
19. Wyss, P. C.; Gerber, P.; Hartman, P. G.; Hubschwerlen, C.; Locher, H.; Marty, H.-P.; Stahl, M. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening. J. Med. Chem. 2003, 46, 2304-2312.
20. Mattioni, B. E.; Jurs, P. C. Prediction of dihydrofolate reductase inhibition and selectivity using computational neural networks and linear discriminant analysis. J. Mol. Graphics Modell. 2003, 21, 391-419.
21. Catalyst, version 4.7; Accelrys Inc.: San Diego, CA, 2002.
22. MDL Information Systems Inc., www.mdli.com.
23. Yuthavong, Y.; Vilaivan, T.; Chareonsethakul, N.; Kamchonwongpaisan, S.; Sirawaraporn, W.; Quarrell, R.; Lowe, G. Development of a Lead Inhibitor for the A16V+S108T Mutant of Dihydrofolate Reductase from the Cycloguanil-Resistant Strain (T9/94) of Plasmodium falciparum. J. Med. Chem. 2000, 43, 2738-2744.
24. Tarnchompoo, B.; Sirichaiwat, C.; Phupong, W.; Intaraudom, C.; Sirawaraporn, W.; Kamchonwongpaisan, S.; Vanichtanankul, J.; Thebtaranonth, Y.; Yuthavong, Y. Development of 2,4-Diaminopyrimidines as Antimalarials Based on Inhibition of the S108N and C59R+S108N Mutants of Dihydrofolate Reductase from Pyrimethamine-Resistant Plasmodium falciparum. J. Med. Chem. 2002, 45, 1244-1252.
25. Toyoda, T.; Brobey, R. K. B.; Sano, G.; Horii, T.; Tomioka, N.; Itai, A. Lead discovery of inhibitors of dihydrofolate reductase domain of plasmodium falciparum dihydrofolate reductase-thymidylate sintase. Biochem. Biophys. Res. Commun. 1997, 235, 515-519.
26. Sutter, J.; Guner, O. F.; Hoffman, R.; Li, H.; Wadman, M. Effect of variable weight and tolerances on predictive model generation. In Pharmacophore Perception, Development, and Use in Drug Design; Guner, O. F., Ed.; International University Line: La Jolla, CA, 1999; pp 501-511.
27. For cost analysis, see Catalyst 4.7 documentation at www.accelrys.com/ doc/life/catalyst47/help/HypoGenAlgRef.doc.html.
28. Wilson, D. K.; Tarle, I.; Petrash, J. M.; Quiocho, F. A. Refined 1.8 Å structure of human aldose reductase complexed. with the potent inhibitor zopolrestat. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9847-9851.
29. Costantino, L.; Rastelli, G.; Gamberini, M. C.; Vinson, J. A.; Bose, P.; Iannone, A.; Staffieri, M.; Antolini, L.; Del Corso, A.; Mura, U.; Albasini, A. 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J. Med. Chem. 1999, 42, 1881-1893.
30. Costantino, L.; Rastelli, G.; Vianello, P.; Cignarella, G.; Barlocco, D. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. Med. Res. Rev. 1999, 19, 3-23.
31. Dean, P. M., Ed. Molecular Similarity in Drug Design; Blackie Academic & Professional: London, 1995; pp 111-137.
32. Ihlenfeldt, W. D.; Takahashi, Y.; Abe, S.; Sasaki, S. Computation and management of chemical properties in CACTVS: an extensible network approach toward modularity and compatibility. J. Chem. Inf. Comput. Sci. 1994, 34, 109-116.
33. SUBSET is available at http://cactus.nci.nih.gov/SUBSET/.
34. Catalyst 4.7 documentation at www.accelrys.com/support/life/ catalyst/hypogen.html.
35. Smellie, A.; Teig, S. L.; Towbin, P. Poling: promoting conformational variation. J. Comput. Chem. 1995, 16, 171-187.